Insider Buying: Biodesix (NASDAQ:BDSX) Director Acquires 80,000 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 80,000 shares of the stock in a transaction on Friday, January 23rd. The stock was purchased at an average cost of $11.81 per share, for a total transaction of $944,800.00. Following the acquisition, the director owned 1,543,210 shares of the company’s stock, valued at $18,225,310.10. This trade represents a 5.47% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Biodesix Stock Performance

Shares of NASDAQ BDSX traded up $1.03 during midday trading on Tuesday, hitting $11.12. 67,524 shares of the company’s stock traded hands, compared to its average volume of 4,904,886. The firm has a fifty day moving average of $7.67 and a 200 day moving average of $7.69. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The stock has a market capitalization of $88.48 million, a price-to-earnings ratio of -2.00 and a beta of 0.60. Biodesix, Inc. has a 1 year low of $3.44 and a 1 year high of $21.60.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.60) by $0.44. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. The business had revenue of $21.77 million for the quarter, compared to the consensus estimate of $20.98 million. On average, analysts forecast that Biodesix, Inc. will post -0.35 earnings per share for the current year.

Analyst Ratings Changes

BDSX has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $32.50.

Hedge Funds Weigh In On Biodesix

Institutional investors have recently bought and sold shares of the business. Aberdeen Group plc purchased a new position in Biodesix during the 4th quarter worth $1,784,000. XTX Topco Ltd raised its stake in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after buying an additional 102,494 shares during the last quarter. Oracle Investment Management Inc. acquired a new stake in Biodesix in the 3rd quarter worth approximately $113,000. Finally, Millennium Management LLC purchased a new stake in shares of Biodesix during the third quarter valued at $113,000. Institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.